← All trials
NCT05195710
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 16, 2022
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Jan 19, 2022
- Last posted
- Nov 22, 2022
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- Sirtex MedicalCollaborator
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.